A novel dynamic field-matching technique for treatment of patients with para-aortic node-positive cervical cancer: Clinical experience

Baden, C.J.; Whitley, Alexander C.; López-Araujo, J.; Popple, Richard A.; Duan, Jun; Kim, Robert

doi:10.1016/j.rpor.2015.09.003

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless, toxicity is also a concern and have been previously reported [19] in smaller retrospective studies. The impact of intensity modulated radiotherapy (IMRT) or arc therapy in lowering the toxicity rates has been demonstrated in some small studies as well [12][13][14][15][20][21][22]. In the United States, Osborn et al (2018) [23], in a study with 103 patients, showed how technology may impact survival on positive PAN cervical cancer patients, particularly the use of 18 FDG-PET scans for diagnosis and staging and IMRT technique for treatment.…”

Section: Resultsmentioning

confidence: 99%

Curative treatment for stage IIIC2 cervical cancer: what to expect?

Mauro,

Calheiros,

Vonsowski

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background Since the GOG125 study, treating radically patients with positive para-aortic lymph nodes has been a valid approach. Nevertheless, literature lacks data on how to better treat these patients since they are usually excluded from trials. In this study, we aimed to report the outcomes of patients with advanced cervical cancer and positive para-aortic lymph nodes (PAN) treated in a single tertiary/academic institution and try to identify variables that may impact survival. Materials and methods We retrospectively reviewed patients with positive para-aortic lymph nodes treated in our institution. Demographic variables and treatment options were assessed and their impact on overall survival (OS), locorregional control, distant metastasis free survival, and para-aortic lymph node progression was analyzed. Results We assessed 65 patients treated from April 2010 to May 2017. Median OS was 38.7 months. Median locorregional and para-aortic progression free survivals were not reached. Median distant metastasis progression-free survival was 64.3 months. Better ECOG performance status (p > 0.001), concurrent chemotherapy (p = 0.031), and brachytherapy (p = 0.02) were independently related to better overall survival. Conclusion Patients with current stage IIIC2 cervix cancer may present long term survival. Treating positive PAN cervical cancer patients with concurrent chemoradiation including brachytherapy with curative intent should be standard. Poor PS and more advanced pelvic disease may represent a higher risk for worse outcomes. Distant metastases are still a challenge for disease control.

show abstract